How Manufacturers Need To Shore Up Fragile Supply Chains To Prevent Antibiotics Shortages
The potential of an impending “apocalypse” of antibiotic drug shortages means that the pharmaceutical industry should pay careful attention to managing fragile supply chains for these drugs. A report details how manufacturers can manage these supply chains to avert potential shortages.
You may also be interested in...
Sanofi has announced plans to create the world’s second-largest API manufacturer to help ease European drugmakers’ dependence on supplies of raw materials from China and India.
Although compounding of certain shortage drugs is allowed during the public health emergency, remdesivir is off limits due to its complexity. Providers should only use the FDA-approved version of the drug, Gilead’s Veklury, the agency says.
Drug makers win one-month reprieve for their nitrosamine risk assessments for new drug products and approved products.